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Abstract A recombinant rat thyroid hormone receptor ~ (TR~ 
or c-ErbA~l) was produced in E. coli as a non-mutated, non- 
fusioned protein and obtained as an efficient DNA and T3 binding 
protein that could he easily handled in a buffer-soluble state 
(rec-TR~). It was found that nuclear extracts (NE) added to 
rec-TR~ markedly amplified not only DNA binding, which has 
been well documented, but also T3 binding (increased binding site 
concentration), which has not yet been reported. This T3 binding 
amplifying effect on rec-TR~ occurs at low NE protein concen- 
trations that produce no or minimal endogenous TR with respect 
to rec-TR, while similar concentrations of other proteins (e.g. 
ovalbumin or cytosol) only moderately enhanced T3 binding. The 
T3 binding amplifying nuclear factors, which are partly heat- 
labile, appeared as necessary auxiliaries in the analyses of par- 
tialiy purified rec-TR~. A protective ffect of NE against a loss 
of affinity for T3 under the action of antibodies directed to certain 
sequences in the TR~ D domain suggests that nuclear factors help 
rec-TR~ to acquire and/or stabilize a conformation that allows 
the high affinity T3 binding. The nature of this nuclear amplifying 
factor is still unknown: RXR~ which, produced in vitro, could 
amplify binding of the rec-TR~ to a DNA thyroid response ele- 
ment, was unable to display such a rescue of high affinity binding 
sites. 
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1. Introduction 
The thyroid hormone 3,5,3'-triiodo-L-thyronine (T3) acti- 
vates nuclear T3 receptors (TR) which bind to thyroid response 
elements (TRE) in target genes. Two major TR isoforms have 
been identified, TR~ and TRfl (ill and f12) that are encoded by 
two homologous c-erbAa and fl genes located on different 
chromosomes [1,2]. The TR belong to the steroid/thyroid/reti- 
noid hormone nuclear eceptor superfamily, a group of struc- 
turally related ligand-activated transcription factors. Like all 
nuclear eceptors, TR possess a highly conserved cystein-rich 
DNA binding domain (C or DBD), and a long, less-conserved 
C-terminal ligand binding domain (E/F or LBD), both domains 
being separated by a short variable and flexible hinge domain 
(D). The LBD exhibits high specificity for the ligand and con- 
tains sub-regions involved in transcriptional activation/repres- 
sion and in dimerization [3-5]. Recent findings indicate that the 
D domain must also be involved in hormone binding [6-9] and 
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transcriptional activation [10]. A series of recent reports hows 
that TR interaction with TRE, and T3-mediated transcriptional 
activity of TR, are amplified by other nuclear auxiliary proteins 
(TRAP) [11,12], including the retinoid receptors RXR [13-15]. 
Analysis of functional regions in TR would be helped by the 
provision of sufficient amounts of purified receptors. Purifica- 
tion of TR from tissues was unsuccessful, due to low abundance 
and poor stability [16-18]. Later on, recombinant TR were 
produced from c-erbA~l and fll cDNAs mainly using E. coli 
[19-21]. Analysis and purification of recombinant TR are fre- 
quently hindered by their poor solubility which led to the use 
of detergents; this may impair T3 binding estimation and stud- 
ies of structural changes that can occur after binding to 
hormone or DNA. We recently produced in E. coli an unfu- 
sioned, unmutated rat c-ErbAczl protein (rec-TR~) that could 
be handled in a soluble form in low ionic strength buffer in the 
absence of detergents. We analyzed its reactivity towards ev- 
eral site-directed antibodies raised against different c-ErbA~z 
peptides [9]. In this previous work, we observed that addition 
of serum proteins as well as ovalbumin, at 1 mg/ml, could 
induce an increase in the number of T3 binding sites detected 
in the rec-TR~ preparations. Here we show for the first time 
that low amounts of nuclear extracts markedly and specifically 
enhance T3 binding to rec-TRc~ and become necessary auxiliary 
factors for estimation of T3 binding sites in purification proto- 
cols. These specific nuclear factors are most probably involved 
in acquisition and/or stabilization of a functioal conformation 
for T3 binding. 
2. Materials and methods 
2.1. Production and partial purification of recombinant rat thyroid 
hormone receptor ot (rec-TRc~) 
The coding sequence ofa rat c-erbAcO cDNA (kindly given by R. 
Evans) was cloned under the control of a strong isopropyl-thiogalacto- 
side (IPTG)-inducible promoter (pTrc99A vector; Pharmacia, France). 
Isolation of the synthetized protein was undertaken as previously de- 
scribed [9]. Briefly, 3 h after induction with 1 mM IPTG, cells were lysed 
in the presence of 1 mM phenylmethylsulfonyl fluoride (PMSF) by 
successively adding lysozyme, Na-deoxycholate nd DNase I. The cells 
were washed in the presence of 0.5% Triton X-100 and proteins ex- 
tracted with 5 M guanidine-HCl in20 mM Tris-HCl (pH 8.0). Protein 
refolding was provoked by a 10-fold ilution with buffer A (20 mM 
Tris-HC1, pH 8.0, 10% glycerol, 5mM dithiothreitol (DTT)), contain- 
ing 200 mM NaCI and, after 16 h at 0°C, by dialysing against four 
changes of buffer A plus 200 mM NaC1 over 24 h. Rec-TR~ was 
partially purified: the dialysed cleared bacterial extract was diluted to 
buffer A plus 150 mM NaCI and applied to an heparin-agarose column 
(Bio-Rad; France) previously equilibrated with buffer A plus 150 mM 
NaC1. After washing with the same buffer, the NaC1 concentration was 
raised to 400 mM to elute TRc~. An approximate 10-fold enrichment 
of TRc~ was then obtained leading to a specific activity of 700 pmol 
bound T3 per mg protein, when assayed as described below. T3 binding 
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site recovery was approximately 45% of initial evels. Bacterial extracts 
and partially purified rec-TRct were supplemented with aprotinin (10 
pg/ml) and stored as small aliquots at -80°C. 
2.2. Preparation of nuclear extracts 
Nuclei were purified from rat liver and from mouse Ob 17 adipocytes 
as previously described [22,23]. Nuclei from rat hepatoma cells FAO 
which lack nuclear T3 binding sites [24] (kindly provided by Dr. Guil- 
louzo, Rennes, France) were also purified as described for Ob17 cells 
[23]. Nuclear extracts were obtained using 400 mM KCI in 20 mM 
Tris-HCl, pH 8.0, 1 mM MgC12, and generally stored as small aliquots 
at -20°C. Rat liver cytosol was prepared as the 100,000 × g supernatant 
ofhomogenate (1:4 w/v) in 0.32 M sucrose, 1 mM MgCI2 and after an 
intermediate c ntrifugation step of 1000 × g to isolate the nuclei. 
2.3. T3 binding assays 
T3 receptor site concentration a d affinity for T3 (K~) were estimated 
in saturation experiments u ing [~25I]T3 (3 mCi/~g; Amersham, UK) in 
T3 binding buffer (20 mM Tris-HC1, pH 7.95, 1 mM MgC12, 100 mM 
KC1, 5 mM DTT) [22,23]. Incubations were performed at 0°C for 20 
h. Non-specific binding was estimated in parallel assays in which was 
added an approx. 1000-fold excess of radioinert T3. Bound and free T3 
were separated by the use of a Dowex 1X8 anion-exchange resin that 
binds free T3. Several comparative T3 binding assays were performed 
at 0.2 nM labelled T3 with or without 0.5 pM radioinert T3. These 
assays generally followed a preincubation (3 h, 0°C) of rec-TRct diluted 
in T3 binding buffer in the presence, or not, of the agents to be tested. 
2.4. DNA binding assays 
Binding of rec-TR~ to DNA was studied, as previously described [9], 
by gel-electrophoresis mobility shift assay (EMSA) using a 32P-labelled 
synthetic purified oligonucleotide (5'-CTAGTTCAGGTCATGACC- 
TGAA-3') that after self-hybridization contains the palindromic 
T3 response lement (TRE-pal): rec-TR~ was preincubated for 2 h at 
0°C with nuclear extracts (1 fig protein) or other agents to be tested, 
then for 30 min at 20°C with the 32p-labelled TRE (30 fmol) in 50/11 
DNA binding buffer (20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 
1 mM MgC12, 50 mM NaC1, 2.5 mM DTT, 20% glycerol, 40flg/ml poly 
d(I-C)). Protein-TRE complexes were separated from uncomplexed 
TRE by electrophoresis through 5% polyacrylamide g ls in 0.5 × TBE 
and under 200 V at 4°C. 
2.5. Production of rat RXRot by in vitro translation in reticulocyte 
lysate 
The plasmid pRXR-T7, encoding rat RXR~, was kindly provided by 
Dr. J.A. Gustafsson [25]. RNA resulting from transcription under the 
T7 promoter was then translated in a reticulocyte lysate system in the 
presence or not of [35S]methionine, according to the supplier's recom- 
mendations (NEN-Dupont, Les Ulis, France). Translation products 
were analyzed by SDS-PAGE (8-18%) and fluorography. A single 
35S-labelled band of the expected size was detected. 
2.6. Other products 
Antibodies to a c-ErbAct peptide sequence situated in domain D 
(amino acids 150-166) were obtained in rabbits and previously de- 
scribed as anti-or 150 [8]. Retinoic acid (stereoisomer 9-cis) was obtained 
from Hoffman-Laroche (Basel, Switzerland). Protein concentrations 
were estimated according to Bradford's method, with serum albumin 
as the standard [26]. 
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Fig. 1. Effect of nuclear extracts on T3 binding to recombinant c-ErbA c~l (rec-TR~). Rec-TR~ in E. coli extracts (4-6 pg protein/ml: A, B, C), or 
partially purified (0.6 gtg protein/ml: D), was preincubated (3 h, 0°C) in T3 binding buffer with or without he following agents: frozen nuclear extract 
(NE), ovalbumin (ovalb.), rat liver cytosol (cyt.) or serum, generally added at 0.04 or 1 mg protein/ml final concentration. Incubation with 
[~25IIT3 + radioinert T3, and estimation of specific T3 binding were as described in section 2. (A) Scatchard plots of saturation analysis on rec-TR~ 
with added: (e) -buffer, (©) 0.04 mg/ml rat liver NE (RLNE) (A--A) and (A_ _ -A) ovalbumin at 1.0 or 0.04 mg/ml, respectively, (A) normal rabbit 
serum at 1 mg/ml; the lowest left regression lines, amplified in the insert, show T3 binding data to RLNE (0.04 mg/ml) alone before (co) or after 
(..) freezing. (B) Effect of increasing concentrations of RLNE (e) or Ob 17 adipocyte NE (©- - -©), FAO cell NE (t3) and ovalbumin (A) on [~25I]T3 
(0.2 nM) binding to rec-TR0~. Binding of [~2SI]T3 to RLNE is shown by <~ (in buffer) and * (in the presence of 1 mg/ml ovalbumin). (C and D) 
Comparative effect of different proteins (0.04 or 1.0 mg/ml), and of heating RLNE (60°C, 10 min) (stippled bars), on [~25I]T3 (0.2 nM) binding to 
rec-TRc~, in E. coil extract (C) or partially purified (D). T3 binding to ovalbumin, RLNE (before and after heating) and cytosol alone is shown by 
the shaded part of bars in D. Data values are the mean of duplicate assays in B (one representative of two experimental series) and mean +- S.E.M. 
of three different duplicate assays in C and D. 
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Fig. 2. Binding of recombinant rat c-ErbA~ 1protein (rec-TRc0 to DNA in electrophoresis mobility shift assays: effect of nuclear extracts (A) and 
of an in vitro produced rat RXR~ (B). Rec-TR~ in E. coli extract (2/tg protein) was incubated with a [32P]TRE-pal (30 fmol) after a preincubation 
with rat liver (RL) or Ob 17 adipocyte (ad) nuclear extracts (NE) (2.0 or 0.5/.tg protein) or RXR~ in rabbit reticulocyte lysate (RLys) (2/zl), in DNA 
binding buffer, and analyzed by EMSA as described in section 2. (A) Lanes: 1, control E. coli extract; 2 and 7, rec-TR~; 3, RLNE 2/zg; 
4, rec-TRc~+RLNE 2/zg; 5, rec-TR~+RLNE 0.5/.tg; 6, rec-TR0~+RLNE 2/tg+radioinert TRE-pal × 50; 8, adNE 2/.tg; 9, rec-TR~+adNE 2/lg. 
(B) Lanes: 1, rec-TRm 2, rRXR~ in RLys (2/11); 3, rec-TR~+rRXRc~ in RLys (2/11); 4, same as 3+radioinert TRE-pal × 50. 
3. Results and discussion 
3.1. Nuclear factors markedly and specifically enhance T3 
binding to recombinant thyroid hormone receptor ot 
We previously reported that T3 binding to rec-TR~z in E. coli 
extracts was markedly enhanced when incubation with [125I]T3 
was performed in the presence of 1.0 mg/ml of either ovalbumin 
(which does not bind T3) or serum (which produced a very 
limited amount of T3 binding sites). This effect reflected an 
increase in the number ofT3 binding sites. It was suggested that 
a high protein concentration could help diluted rec-TRcz (4-8 
/zg/ml), stabilizing a proper conformation that would allow T3 
to bind [9]. Fig. 1 shows that such an amplifying effect could 
be obtained, at least as efficiently, with low amounts of nuclear 
extracts (30-40/.tg protein/ml). The effect was the same whether 
nuclear extracts were used after freeze thawing (which pro- 
vokes an important loss of detectable endogenous T3 binding 
sites) or freshly prepared (producing only a very low amount 
of T3 binding sites: approx. 500 fmol/mg protein [22], see Fig. 
1A, insert). The T3 binding amplification by nuclear extracts 
also occurred without any significant change in the Ka for T3 
(Fig. 1A). It was detected and completed within a low protein 
concentration range, a similar plateau being reached at approx. 
40/ag protein/ml whether nuclear extracts were from rat liver 
(main TR content as fll isoform), from mouse Obl 7 adipocytes 
(TR content as c¢ [8]), or from the TR-deficient FAO cells (Fig. 
1B). At this concentration, ovalbumin (Fig. IA-C) and rat liver 
cytosol (Fig. 1C) were far less efficient. 
Moreover, and importantly, nuclear factors were found to 
play a major and unique role when T3 binding was studied with 
partially purified rec-TRa included in the binding tests at 0.4- 
0.8/.tg/ml: without any protein addition a specific binding of T3 
was barely detectable; ovalbumin, even at 1 mg/ml, or cytosol, 
poorly increased T3 binding; a marked amplification was ob- 
tained only with low concentrations of nuclear proteins (Fig. 
1D). This amplification always led to a T3 binding site number 
which was far higher than the low level eventually produced by 
the nuclear extracts (shaded bars in Fig. 1D). In any case, 
heating the nuclear extracts (10 min, 60°C) partly reduced the 
amplifying effect (Fig. 1C and D). The applied heating condi- 
tions were known to be able to totally destroy, in nuclear 
extracts, any T3 binding activity [22] or any amplifying activity 
on TR binding to DNA [11]. Our present finding suggests that 
the nuclear factors that enhance T3 binding to rec-TR~ may 
be heterogeneous. A cooperative effect of some nuclear auxil- 
iary factors helping high affinity ligand binding was similarly 
and recently reported for the purified 1,25-dihydroxyvitamin 
D3 receptor [27] and the ecdysone receptor [28]. 
As evoked above, nuclear extracts are known to play an 
amplifying role in TR binding to DNA whether TR were pro- 
duced by in vitro translation in reticulocyte lysate [11] or in 
bacteria [21]. Working with 32p-labelled oligonucleotides that 
contained TRE sequences, different authors described both an 
increase in the amount of TR bound to TRE and qualitative 
changes with the formation of high Mr complexes with heat- 
labile nuclear TRAP (heterodimers and oligomers in EMSA) 
[12,13]. In the present study, using the EMSA methodology, a 
similar amplifying effect and similar changes in band pattern 
were observed when rec-TR~ was incubated with rat liver nu- 
clear extracts prior to [32p] TRE-pal addition. This is illustrated 
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Fig. 3. Protective ffect of nuclear extract (B) against an alteration of 
the T3 binding property of rec-TRe due to the action of anti-c~150-166 
antiserum compared to preimmune s rum. Scatchard plots of satura- 
tion analysis with T3 performed on rec-TRe (5 Hg/ml) sequentially 
preincubated (1) for 3 h at 0°C, with buffer in A, rat liver nuclear 
extract (35/~g/ml) in B, or ovalbumin (40/lg/ml) in C, (2) then for a 
further 3 h at 0°C after addition of preimmune (©) or anti-~150 (e) 
serum (1 mg proteirdml), before being incubated with increasing con- 
centrations of[~25I]T3, as described insection 2. The final concentration 
of added proteins ranged between 1.00 and 1.04 mg/ml. 
in Fig. 2 which also shows that nuclear extracts from Obl7 
adipocytes give similar esults with a slightly different mobility 
pattern in high Mr oligomeric bands. 
The present results thus indicate that nuclear factors play an 
important and apparently specific role in stabilization or acqui- 
sition of two basal functions of rec-TR~: the effect on DNA 
binding is already well documented while the marked effect 
observed for hormone binding has not yet been reported. 
We then considered two questions: (i) are nuclear factors 
specifically involved in acquisition/stabilization of a preferred 
conformation allowing high affinity T3 binding, or (ii) among 
different classes of nuclear factors that can be implied in this 
effect, are RXR, which are known to dimerize to TR, possible 
candidates to play this role? 
3.2. Nuclear factors are involved in the acquisition-stabilization 
of a prefered conformation that allows high affinity T3 
binding 
To answer the first question we could make use of antibodies 
raised against several restricted sequences in the D and ElF 
domains of TRe and assay for their ability to inhibit T3 binding 
to TRy. Our previous results [8,9] indicate that both the ex- 
treme C-terminus and the C-terminal part of domain D play an 
important role in T3 binding to natural TRe and to an entire 
recombinant TR~ as suggested by previous tudies of T3 bind- 
ing to deleted or mutated proteins [6,7]. More particularly, one 
set of our antibodies, directed against a c-ErbA~ 150-166 se- 
quence (anti-~150) displayed a different behaviour towards nat- 
ural or recombinant TRc~. It decreased the K a for T3 binding 
to rec-TRc~ but not to natural unlinganded TR~z prepared from 
Ob 17 adipocytes, although immunorecognition was character- 
ized in both cases [8,9]. Such a different reactivity to this set of 
antibodies evokes different structural states of the LBD sur- 
rounding the target sequence between both natural and recom- 
binant TRc~. An hypothesis was that natural TRcz could be 
coupled to some nuclear proteins helping this TR acquire a 
conformation more resistant to interaction with anti-ot 150 anti- 
bodies. 
To test this hypothesis, we attempted to reproduce in vitro 
a possible protective ffect of nuclear factors: T3 binding was 
analyzed after sequential preincubations in the presence of 
(i) either buffer, nuclear extract or ovalbumin, and (ii) either 
antiserum to Ot150 peptide or preimmune serum (thus in the 
presence of 1.0-1.04 mg protein/ml, a concentration that per se 
increases the T3 binding site number; see open triangles in Fig. 
1A). As shown in Fig. 3 and as cited above, anti-~150 dramat- 
ically decreased the Ka for T3 (panel A) when compared to 
preimmune serum (decrease of 74 + 2% in 3 experiments). In- 
terestingly, prior addition of rat liver nuclear extracts largely 
prevented rec-TR~ from this dramatic decline of affinity for T3 
due to the antibody (residual decrease of 38 + 3% in 3 experi- 
ments) (panel B). This protective effect could not be reproduced 
when ovalbumin was used instead of nuclear extract (panel C). 
Nevertheless, this marked preventing effect of nuclear factors 
remained incomplete despite the use of an optimal nuclear 
extract concentration, and the affinity did not recover the level 
displayed with preimmune serum. This could be related to the 
in vitro conditions that did not allow a completed effect, or to 
the possible involvement of some post-translational modifica- 
tions that cannot occur in this recombinant TR. 
3.3. The nuclear factor(s) that helps recombinant TRot acquire 
high affinity T3 binding is not a RXRot 
Many studies on TR binding to DNA have demonstrated 
that nuclear proteins, the so-called TRAP, markedly amplified 
the binding of rec-TRc~ to labeled TRE-pal (Fig. 2). Several 
authors reported that this TRAP family included the different 
RXR, particulary the widely distributed products of the RXR 
Ot and fl genes [15,29]. These RXR proteins have been shown 
to increase the binding of TR to TRE by forming heterodimers, 
as demonstrated by the presence of DNA-protein complexes 
that displayed a lower mobility in EMSA. Moreover, RXR may 
also amplify the transcriptional responses to T3-activated TR, 
as suggested by results of co-transfection experiments [13 
15,30,31]. The addition of 9-cis retinoic acid, a specific ligand 
of RXR, may or may not synergistically increase dimerization 
with, and transactivation by, TR [30,31]. A decreased heterod- 
imerization of TR to RXR under 9-cis retinoic acid action that 
favored RXR homodimerization has also been reported [32]. 
In order to see whether RXR could be involved in the ampli- 
fying effect of nuclear extracts on T3 binding, and since what 
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Fig. 4. Analysis of the effect of RXR~ and its ligand 9-cis retinoic acid 
on the T3 binding property of recombinant TRy. Rec-TR~ in E. coli 
extract (6 mg/ml) (A) or partially purified (0.5 mg/ml) (B) were preincu- 
bated for 3 h at 0°C in the presence ofeither buffer (a), rat liver nuclear 
extract (40 mg/ml) (b), rabbit reticulocyte lysate RXRa (c) or control 
(d) (50 mg/ml) without (open bars) or with (stippled bars) added 100 
nM 9-cis retinoic acid, then for 18 h at 0°C with 0.2 nM [LzSI]T3. Data 
are the mean of duplicate assays in one out of three similar experiments. 
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we have described could reflect previous reports on RXR-TR 
interactions, we first sought a possible interference with 9-eis 
retinoic acid. Fig. 4 shows that 100 nM of this RXR ligand was 
without any significant effect on T3 binding to rec-TRct in the 
absence or presence of nuclear extracts. 
We then synthetized a rat RXRc~, described as abundantly 
expressed in rat liver [29], by in vitro transcription/translation 
from a full-length cDNA. This RXR~t preincubated with rec- 
TR~ allowed an amplification of binding of the receptor to [32p] 
TRE-pal with the formation of heterodimers, asshown in Fig. 
2B, and as expected. Nevertheless, RXRc~ did not increase T3 
binding to rec-TRc~ when comparing assays with controls that 
contained the same amount of unprogrammed lysate, whether 
9-cis retinoic acid was present or not, and whether working 
with rec-TR~ in E. coli extracts (Fig. 4A) or partially purified 
(Fig. 4B). RXR gene products, at least of the s-type, therefore 
seemed not to be the T3 binding amplifying factors. The possi- 
ble involvement of other RXR or other nuclear factors/proteins 
(including other nuclear eceptors) has to be explored, as well 
as the possible involvement of chaperone proteins, although it 
has been reported that TR is translated in the DNA binding 
state and not associated with hsp90 [33]. 
In conclusion, our results reveal for the first time that nuclear 
factor(s) are specifically implied in promoting the structural 
maturation of a recombinant TRot that leads to acquisition of 
the high affinity T3 binding site. With this specific role, nuclear 
extracts are thus important auxiliaries in studies of recombi- 
nant TR during purification protocols. In the present work this 
property is observed in vitro on recombinant TRot which was 
denaturated and renaturated. The same results were obtained 
when using recombinant TR directly extracted from bacteria 
by sonication without any denaturing agents, a procedure that 
gave a lower TR extraction yield [9]. These results are reminis- 
cent of a similar role played by a nuclear extract sub-fraction 
that was demonstrated during purification of natural TR. In a 
previous tudy, we demonstrated that this sub-fraction had to 
be added to partially purified TR in order to restore high 
affinity T3 binding sites [34]. It is thus conceivable that in the 
native state in nuclei, TR; at least of the ~ type, exist in a 
more-or-less loose association with factor(s) which would help 
to complete and stabilize the quaternary structure of the TR 
LBD. These factor(s) do not seem to imply the widely repre- 
sented RXR~, and thus differ, at least in part, from those 
already described for efficient arget DNA binding. Analysis of 
their nature deserves further investigation to understand TR 
function and facilitate structural studies on the recombinant 
over-expressed receptor. 
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